Pipeline

Product portfolio

Program

Indication

Insilico design

Discovery

Preclinical

Phase-1

Phase-2 & 3

Disease Area

Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2

Oral insulin

Diabetes (Type 1 & 2)

Disease Area

Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2

Thermostable Insulin

Diabetes (Type 1 & 2)

Disease Area

Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2

Insulin-Glp 1 Dual agonist

Diabetes (Type 1 & 2)

Disease Area

Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2

Non-opiate Analgesic

Acute + chronic pain

Disease Area

Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2

Hyaluronidase (enzyme)

Excipient

REFERENCES FOR MARKET SIZES

https://www.marketwatch.com/press-release/oral-insulin-market-share-upcoming-trends-size-key-segments-growth-status-and-forecast-2027-2022-03-08

https://www.globenewswire.com/news-release/2021/10/27/2321383/0/en/USD-27-71-Billion-Industry-Human-Insulin-Market-Size-Share-Growth-Factors-Restraining-Factors-Trends-Analysis-Report-2026.html

https://www.alliedmarketresearch.com/pain-management-therapeutics-marketOpioid market space

https://www.bccresearch.com/market-research/pharmaceuticals/opioid-drugs-global-markets.html

Primary TTP

Oral long acting, Basal insulin

Room temperature stable insulin

Insulin-GLP-1 dual agonist

Non-addictive analgesic

Novel Hyaluronidase for absorption enhancement